Some fancy text

Some fancy text

Some fancy text

Available as an intravenous solution at the strength of 27 mCi/1mL.

Needs to be stored according to radio-pharmaceutical storage guidelines.

May cause adverse effects where dose modification is required.

Mechanism of Action:

Absorption:

Maximum blood concentration = 6.58 ng/mL

Distribution:

Volume of distribution = 123 L

60% to 70% bound to human plasma proteins

Elimination:

Elimination half-life = 41.6 hours (68.8%)

Clearance (CL) = 2.04 L/h (31.5%)

Primarily eliminated renally

Pluvicto™ (Lutetium-177 Vipivotide Tetraxetan) FDA approved in the VISION Phase III randomized, multicenter, open-labeled clinical trial of 831 patients with progressive PSMA-positive mCPRC.

Some fancy text

Some fancy text